China Pharmaceutical Group Co., Ltd. was established at 1987 with its registered address at No.20 Zhichun Road, Haidian District, Beijing. Its legal representative is Liu Jingzhen, who is directly managed by the State-owned Assets Supervision and Administration Commission of the State Council. It is the only central enterprise that focuses on life and health, and it is also the central medical reserve unit. At present, it has industrial manufacturing, scientific research and development, logistics and distribution, professional exhibitions, engineering technology, medical and health care, retail chain, international finance and financial investment.
The Development Course of China Pharmaceutical Group
1.In 2003, as a member of the logistics support group of the National Command for the Prevention and Treatment of SARS, we mobilized more than 100 enterprises under the group and allocated medical materials for the prevention and treatment of SARS to more than 20 provinces, autonomous regions and municipalities directly under the Central Government, with a total amount of1.30 billion yuan.
2. In 2008, all efforts were made in earthquake relief, and the reserve of medical materials reached 300 million yuan, which played an important role in earthquake relief.
3.20 10 Sinopharm Group signed a strategic agreement to build a large-scale modern industrial base of traditional Chinese medicine preparations in central Jianhua.
In April 2012, the signing ceremony of modern sunshine medical examination was formally held for Sinopharm Group's investment holding, and Sinopharm Sunshine Health Technology Co., Ltd. was established as a joint venture with Beijing Modern Sunshine Health Technology Co., Ltd.
On 20/513, sinopharm Zhongyuan hospital management co., ltd was established, with five hospitals under its jurisdiction.
6. In 2020, China Pharmaceutical Group set up a special fund of RMB 654.38+0 billion to be used exclusively for the novel coronavirus epidemic. In that year, he was selected into the list of scientific and technological reform demonstration enterprises of the State Council SASAC.
7.202 1 year, the inactivated vaccine developed in COVID-19 was approved and used urgently by people aged 3- 17. Signed a strategic cooperation agreement with SINOMACH to carry out all-round and multi-field in-depth cooperation, and * * * promoted the implementation of the national strategy.
8. In 2022, Sabin strain polio inactivated vaccine independently developed and produced passed WHO pre-certification.
abstract
China Pharmaceutical Group has built a self-controllable, complete and complete pharmaceutical R&D, manufacturing, circulation, medical and health care industrial chain around four core businesses: pharmaceutical technology research and development, pharmaceutical industrial manufacturing, pharmaceutical trade circulation and medical and health protection. At the same time, it has also developed six supporting industries: medical equipment, life and health, medical care, medical service, medical beauty and medical exhibition, effectively improving and extending the whole industrial chain of medical care and extending it to the whole life cycle of life and health. In the process of development, Lian Heng will be integrated, and the Group will continue to be stronger, better, bigger, more sophisticated and more specialized, so as to build a world-class comprehensive pharmaceutical and health industry group with global competitiveness.